If you're one of nearly 200 million Americans living with a chronic disease, Medicare policy debates can often feel far removed from your daily life. But sometimes, a technical-sounding proposal can have real consequences for the treatments you rely on — and that's exactly what's happening right now. The Centers for Medicare and Medicaid Services (CMS) is considering a change to how it classifies certain drugs under the Medicare Drug Price Negotiation Program (MDPNP) establis

May 20, 2026 (Washington, D.C.) The Partnership to Fight Chronic Disease (PFCD) released the following statement in advance of this week’s anticipated Senate vote-a-rama on the reconciliation bill: “The Partnership to Fight Chronic Disease urges Congress to carefully consider the unintended consequences that foreign drug pricing policies could have for Americans living with one or more chronic conditions. “Patients living with cancer, Alzheimer’s disease, autoimmune disorders

April 17, 2026 (Washington, D.C.) The Partnership to Fight Chronic Disease (PFCD) released the following statement today in response to recent analyses related to Alzheimer’s disease. “The recent review of anti-amyloid Alzheimer’s therapies highlights the complexity of measuring progress against a devastating disease, but its conclusions should be viewed with important context. By combining older, unsuccessful therapies with newer treatments that have demonstrated the abilit

For millions of Americans living with cancer, access to innovative treatments is urgent and often lifesaving. The U.S. has long led the world in developing cutting-edge therapies, giving patients earlier access to new medicines and contributing to improved survival rates and quality of life. With 345 cancer medicines launched over a twelve-year span compared to just 191 in the U.K., a difference that translates directly into more treatment options and better outcomes for pati

Patients lose access to lifesaving therapies when governments impose drug price controls, and the consequences are measured in delayed treatment, depleted research pipelines and lives cut short, according to a new research analysis from the Information Technology and Innovation Foundation (ITIF). ITIF examined how European drug pricing policies drove the continent's fall from global biopharmaceutical leadership. While compiling and assessing existing research on the patient i